European Union* facilitates the realization of a platform to develop adult stem cells into a fast and safe preparation to treat spinal cord lesions.
Under the leadership of Neuroplast BV, various biotechnology firms including PathoFinder BV, Maastricht Instruments BV, University Maastricht department MHeNS and Neuroplast BV work closely together within Brightlands Maastricht Health Campus to develop an optimal, safe adult stem cell preparation for the treatment of spinal cord injuries. As animal experiments did show very promising results regarding the treatment of the persistent invalidating and debilitating consequences of spinal cord lesions, one might extrapolate a significant increase of quality of life in patients suffering these lesions when treated with autologous stem cells. Innovating aspects of the platform (Amaryllis) include the fast processing of the stem cells (within 6 hours), without manipulation. In the same time the preparation will be screened for pathogenic micro-organisms, preventing for antibiotic co-medication. Another advantage is the platform’s mobile design, allowing for worldwide application in the vicinity of the patient.
Dutch Life Sciences Conference 2015
HUMANIMAL nominates Neuroplast BV for their One Health Innovation Challenge prize 2015
The Flevoland Humanimal Health Innovation Challenge nominates in 2015 Neuroplast for their annual Health Innovation Challenge prize because of Amarna’s development of an innovative platform (Amaryllis) to enable them to produce a fast and safe preparation of stem cells for the treatment of neurodegenerative diseases including parkinsonism, dementia and spinal cord injuries. The advantages of Amaryllis comprise the negative selection of pro-inflammatory components out of the crude bone marrow stem cell preparation, thus avoiding both eventual graft-versus-host reactions and eventual adverse events due to manipulation of stem cells. Another significant advantage is the screening for pathogenic micro-organisms during this last (fast: within 6 hours) process, thus enabling for omission of preventive antibiotic co-medication.
OP-ZUID European Innovation-Program for Southern Netherlands